30th Nov 2005 10:35
Provalis PLC30 November 2005 Provalis plc Non-Executive Director Resignation Provalis plc (LSE: PRO), the international Medical Diagnostics andPharmaceuticals Group, announces that Christine Soden has stepped down as anon-executive Director, with immediate effect, in order to concentrate on herrole as Chief Financial Officer of BTG plc. She was due to retire by rotationat this year's Annual General Meeting and accordingly the resolution proposingher re-appointment will not be put to the meeting. Frank Harding, Chairman of Provalis plc, said, "Christine has been a non-executive director of Provalis, and Chaired the AuditCommittee, for over five years. I would like to take this opportunity ofthanking Christine for her significant contribution and wish her well for thefuture." 30 November 2005 For further information:- Provalis plcMr Lee Greenbury, Company Secretary 01244 833402 College HillAdrian Duffield/Corinna Dorward 020 7457 2815/2803 Notes to Editors Provalis plc (LSE: PRO) is an international healthcare group with two operatingbusinesses:- • Medical Diagnostics - develops medical diagnostic products for chronic disease management for sale to world markets. The business' principal products are in2itTM A1C and Glycosal(R), both diabetes diagnostic tests. • Pharmaceuticals - sells and markets its own, and third party, branded, prescription medicines in the UK and Ireland to GPs and hospitals through its regionally managed sales force. The business' principal product is Diclomax(R), a medicine for use in the treatment of musculo-skeletal disorders, and it also sells products in the areas of osteoporosis, migraine and dermatology. Visit Provalis' Website at http://www.provalis.com "Safe Harbor" Statement under the US Private Securities Litigation Reform Act of1995: Statements in this announcement that relate to future plans, expectations,events, performances and the like are forward-looking statements as defined inthe US Private Securities Litigation Reform Act of 1995. Actual results ofevents could differ materially from those described in the forward-lookingstatements due to a variety of factors. Such factors include, among others: theviability of the Group's products, which are at various stages of development;the generation of sufficient operating cash flow by the Group's pharmaceuticaland medical diagnostic businesses to finance the ongoing development of thesebusinesses as well as the Group's research and development activities; thesuccess of the Group's research and development strategy and activities;uncertainties related to future clinical trial results and the associatedregulatory process; the execution and success of collaborative agreements withthird parties; availability and level of reimbursement for the Group's productsfrom government health administration authorities or other third-party payors;the rate of net cash utilisation within the Group and, hence, the Group'spossible need for additional capital in the short, medium and/or long term; theGroup's intellectual property position and the success of patent applicationsfor its products and technologies; the Group's dependence on key personnel;general business and economic conditions; the impact of future laws, regulationsand policies; stock market trends in the Group's sector; and other factorsbeyond the Group's control that may cause the Group's available capitalresources to be used more quickly than expected. These and other factors thatcould affect the Company's future results are more fully described in itsfilings with the US Securities and Exchange Commission, in particular the latest20-F filing, copies of which are available from the Company Secretary at theCompany's registered address. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Proservice Bldg